Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT06129799
Recruiting Observational

Exercise CMR in (p)LF-LG AS

NCT06129799 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Göttingen
Phase
Observational
Started
2023-11-01
Last updated
2023-11-13

Condition(s) studied

Aortic Stenosis, Severe

Study summary

Patient with paradoxical or conventional low-flow low-gradient aortic stenosis on echocardiographic assessment will undergo physiological exercise-stress CMR in addition to guideline recommended surveys prior to TAVR.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * paradoxical or conventional severe low-flow low-gradient aortic stenosis Exclusion Criteria: * CMR incapable device * unable to undergo 40 min scan (can not lie flat, claustrophobia) * renal insufficiency (eGFR \<30 ml/min/1.73m²) * allergy against contrast agent * unable to exercise in supine position

Primary outcome measure(s)

  • Composite of events: number of participants with cardiovascular death or heart failure hospitalisation — 12 months

Trial sites (1)

FacilityCityRegionStatus
University Hospital Goettingen Göttingen Germany Recruiting

More University of Göttingen trials in Germany

InsightRP2 Registry Recruiting
TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study Active, not recruiting

Other trials for the same condition

Valvosoft Outcomes Registry for Real-World Evidence Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06129799 on ClinicalTrials.gov ↗ ← All trials in Germany